radium | THE "NEW" PROSTATE CANCER INFOLINK

Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
This web site is a service of Prostate Cancer International.

Prostate Cancer International is a non-profit for 2012 as rated by Great NonProfits
Other PCI web sites

El Cáncer de Próstata Latinoamérica
Prostate Cancer Africa
Prostate Cancer Caribbean
Solidarité Prostate InfoLink
The "New" Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Copyright © 2008-11 Prostate Cancer International, Inc.

Full data report from the ALSYMPCA trial of radium-223 presented

Posted on September 26, 2011 by Sitemaster

According to a company media release, the full results of the ALSYMPCA trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin^®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: Alpharadin, outcome, radium, radium-223, survival | Leave a Comment »

THE "NEW" PROSTATE CANCER INFOLINK

Other PCI web sites

Full data report from the ALSYMPCA trial of radium-223 presented

Video Interviews

Find Clinical Trials

In a New York Minute

Hot Posts …

… and Archives

Follow “THE "NEW" PROSTATE CANCER INFOLINK”